Core Points - Golar LNG Limited has successfully closed a new $1.2 billion asset-backed debt facility agreement for refinancing FLNG Gimi, replacing an existing facility with an outstanding amount of $627 million as of Q3 2025 [1][2] - The new debt facility has a 7-year tenor, a 16-year amortization profile, and incurs interest at SOFR plus a margin of 2.50% per annum [2] - Golar's 70% share of the net liquidity released from the refinancing amounts to approximately $400 million after repaying the existing Gimi debt facility and unwinding the existing interest-rate swap [2] - The CEO of Golar, Karl Fredrik Staubo, expressed satisfaction with the strong interest from leading international banks, indicating improved terms compared to the initial financing facility [3] - The new facility demonstrates the bankability of Golar's FLNG assets once operational, with a projected debt to EBITDA ratio of approximately 5.5x [3]

Core Insights - Xeriant Inc. is expanding its technology portfolio under the leadership of Brig. Gen. (Ret.) Blaine Holt, focusing on high-growth sectors such as artificial intelligence, quantum computing, and data science [1][6] - The company aims to create a collaborative technology ecosystem to accelerate the development of disruptive technologies [3] - Xeriant seeks to identify and advance innovations across aerospace and other sectors, positioning itself as a hub for transformative technologies [6] Company Strategy - Brig. Gen. Holt will target successful operating companies for acquisitions, licensing opportunities, or strategic partnerships to enhance Xeriant's technology offerings [1] - The company is assembling a diverse team of innovators to foster interdisciplinary teamwork and strong relationships within the technology landscape [3][4] - Xeriant's mission includes partnering with and acquiring strategic interests in visionary companies that align with its goals [8] Leadership Background - Brig. Gen. Holt has a distinguished career in both military and private sectors, including roles as the U.S. deputy military representative to NATO and CEO of AlchemAI, a software company focused on AI technology [4][5][7] - His experience in logistics, operations, and diplomacy is expected to provide valuable insights into identifying opportunities and synergies for Xeriant [4][7] Company Overview - Xeriant, Inc. is dedicated to the discovery, development, and commercialization of transformative technologies, including advanced materials marketed under the DUREVER™ brand [8] - The company's advanced materials include NEXBOARD™, an eco-friendly composite construction panel designed to replace traditional building materials [8]

Core Insights - Skyworks Solutions, Inc. will participate in a fireside chat at the UBS Global Technology and AI Conference on December 2, 2025, at 2:15 p.m. MST [1] - The event will be available for live webcast and archived for replay for one week on Skyworks' website [2] Company Overview - Skyworks Solutions, Inc. is a leading developer and manufacturer of high-performance analog and mixed-signal semiconductors for various applications, including aerospace, automotive, broadband, cellular infrastructure, connected home, defense, entertainment, gaming, industrial, medical, smartphones, tablets, and wearables [3] - The company operates globally with facilities in Asia, Europe, and North America and is a member of the S&P 500 market index [4]

Atlanta, GA, Nov. 25, 2025 (GLOBE NEWSWIRE) -- ScanTech AI Systems Inc. (the "Company" or "ScanTech AI") (Nasdaq: STAI), a developer of advanced AI-powered security screening and imaging systems, today announced a strategic partnership with unival group, a global leader in security systems integration headquartered in Bonn, Germany. The partnership combines ScanTech AI’s SENTINEL® CT security platform—featuring multi-angle computed tomography, AI-based automatic threat detection, and real-time analytics, wi ...

Core Viewpoint - Nuvectis Pharma, Inc. is hosting a virtual Key Opinion Leader Meeting on December 2, 2025, to discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, particularly its combination with osimertinib in non-small cell lung cancer [1][2]. Company Overview - Nuvectis Pharma, Inc. is a clinical stage biopharmaceutical company focused on developing innovative precision medicines for serious unmet medical needs in oncology [1][8]. - The lead drug candidate, NXP900, is an oral small molecule inhibitor targeting the SRC Family of Kinases (SFK), including SRC and YES1, designed to inhibit both catalytic and scaffolding functions of the SRC pathway [6][8]. NXP900 Development - NXP900 has completed a Phase 1a dose escalation study in patients with advanced solid tumors and is currently undergoing a Phase 1b single agent dose expansion study [7][8]. - A drug-drug interaction study has been completed, supporting the initiation of enrollment in the Phase 1b dose expansion combination arm, expected to begin by the end of 2025 [7]. Key Opinion Leaders - The meeting will feature Dr. Alexander Spira, Chief Scientific Officer of NEXT Oncology, and Dr. Asier Uncita-Broceta, Professor of Chemistry at the University of Edinburgh, who will discuss NXP900's development program and clinical data [2][4][5].

First-of-its-Kind Investment Provides Direct Exposure to Telegram's $3 Billion Projected Annual Revenue paying ~9% APY with Convertible discount of 20% in a Telegram Change of Control Scenario, in addition, ATON will use the 9% APY to accumulate more TON Coin for its Digital Asset TreasuryTORTOLA, BVI, Nov. 25, 2025 (GLOBE NEWSWIRE) -- AlphaTON Capital Corp. (NASDAQ: ATON), a leading digital asset technology company focused on the Telegram and TON ecosystem, today announced its strategic interest in acquiri ...

Core Viewpoint - Compass Therapeutics, Inc. is actively engaging with investors through participation in key healthcare conferences in December 2025, highlighting its focus on oncology and proprietary antibody-based therapeutics [1][2]. Group 1: Upcoming Investor Events - Compass Therapeutics will participate in the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, at 8:00 AM ET in New York, NY [2]. - The company will also attend the 8th Annual Evercore Healthcare Conference on December 4, 2025, at 10:00 AM ET in Coral Gables, FL [2]. - Presentations from these events will be archived for 90 days on Compass' Events page, allowing for virtual/replay availability [2]. Group 2: Company Overview - Compass Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary antibody-based therapeutics for oncology [4]. - The company’s research emphasizes the interplay between angiogenesis, the immune system, and tumor growth, aiming to create a robust pipeline of novel product candidates [4]. - The therapeutic strategies include targeting angiogenesis, inducing immune responses, and overcoming immunosuppressive mechanisms utilized by tumors [4]. - Founded in 2014, Compass Therapeutics is headquartered in Boston, Massachusetts [4].

Core Insights - DraftKings has launched a Spanish-language experience within its Sportsbook & Casino app, reflecting the company's commitment to customer-centric services and expanding its market reach [1][2]. Group 1: Product Development - The new Spanish-language functionality aims to enhance the user experience for Spanish-speaking players, who represent a growing segment of DraftKings' customer base [2]. - This feature will be rolled out initially to select existing customers in the U.S. and Ontario, with plans for broader availability in the coming weeks [2][3]. - The Spanish-language experience will encompass the entire customer journey, including account onboarding, navigation, betting content, gameplay, promotions, customer support, and responsible gaming resources [3]. Group 2: Company Overview - DraftKings Inc. is a digital sports entertainment and gaming company founded in 2012, headquartered in Boston, offering products in daily fantasy, regulated gaming, and digital media [4]. - The company operates sports betting in 28 states, Washington, D.C., Ontario, Canada, and Puerto Rico, and provides iGaming services in five states and Ontario [4]. - DraftKings is an official partner of major sports leagues, including the NFL, NHL, PGA TOUR, WNBA, UFC, NBA, and MLB, and also owns the leading digital lottery courier app, Jackpocket [4].

Core Insights - Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies for cancer and autoimmune diseases [1][3] Company Overview - The company utilizes a proprietary iPSC product platform to create multiplexed-engineered master iPSC lines and manufacture off-the-shelf, iPSC-derived cell products [3] - Fate Therapeutics has established a leadership position in the clinical development of iPSC-derived natural killer (NK) cell and T-cell product candidates, which are designed to deliver multiple therapeutic mechanisms [3] - The company is headquartered in San Diego, California [3] Upcoming Events - Fate Therapeutics will present at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, in New York [1] - Company management will participate in a fireside chat at 9:00 AM ET and a cell therapy panel discussion at 12:00 PM ET [1]

Core Insights - Black Rock Coffee Bar, Inc. will participate in the Morgan Stanley Global Consumer & Retail Conference on December 2, 2025, in New York, NY, including 1x1 meetings and a fireside chat at 3:00 p.m. EST [1] - A live webcast of the fireside chat will be available on the investor relations section of Black Rock Coffee Bar's website [2] Company Overview - Black Rock Coffee Bar is a high-growth operator of guest-centric, drive-thru coffee bars, offering premium caffeinated beverages and an elevated in-store experience [3] - Founded in 2008 in Beaverton, Oregon, Black Rock Coffee Bar has grown from a single 160 square foot coffee bar to one of the fastest-growing beverage companies in the U.S. by revenue [3] - The company is the largest fully company-owned coffee retailer in the country, with over 170 locations across seven states, from the Pacific Northwest to Texas [3]